This 1 Number Could Completely Change Your Opinion of Moderna
Moderna (NASDAQ: MRNA) exploded onto the scene when it began development of its coronavirus vaccine. The company had been around for a decade -- but this new mission attracted all eyes. Success of the program led to share gains of more than 400% in 2020. Since, the company has reported billions of dollars in revenue and profit from its vaccine.
But Moderna is no longer the brightest star in the investment sky. Investors have worried about the company's vaccine revenue over the long term. The concern is revenue may sink like a stone in a post-pandemic world. As a result, shares have dropped more than 40% this year. But Moderna recently offered us one number that's pretty reassuring. In fact, if you've been doubting Moderna's long-term potential, this number may completely change your mind.
So, what is this magic number? It has to do with the long-term revenue opportunity for coronavirus vaccines. First, a bit of background on the past and current revenue situation. Moderna has been selling its vaccine directly to governments around the world. In this context, the price per dose has been lower than if Moderna was selling directly to drug distributors.
Source Fool.com
